Talmo Paul

Chief Technology Officer

Paul Talmo has served as our Chief Technology Officer since August 2023. Prior to this, Mr. Talmo served in roles of increasing responsibility at the Company since 2017, including serving as our Chief Strategic Officer. Mr. Talmo has over 25 years of experience commercializing technologies within the medical device and service industries, including medical devices, implantable materials, as well as imaging and diagnostic technologies services. Prior to joining TELA, Mr. Talmo also spent 16 years at LifeCell Corporation, a regenerative medicine company which was acquired by Allergan plc in February 2017, and was an impetus behind the transformation of a burn focused company into a soft tissue reconstruction…

Biography from the company’s latest DEF 14A proxy statement

1Open-market trades

1Ticker

+3.49%Avg 90d after buys

—Avg 90d after sales

−63.6%Avg 180d after buys

—Avg 180d after sales

TELA price and prints

Full TELA chart

TELA Bio, Inc. 1 open-market print by this insider, 10/24/2024 – 10/24/2024. Triangles mark only their Form 4 purchases and sales.

TELA adjusted close▲ buy▼ sale

TELA trades

Date	Form 4	Ticker	Side	Shares	Value	90d	180d
10/24/2024	Form 4	TELATELA Bio, IncChief Technology Officer TELA Bio, Inc · Surgical & Medical Instruments & ApparatusIndustrySurgical & Medical Instruments & ApparatusMkt cap (est.)$63.31MPrice$1.2552w high$1.6152w low$0.56	BUY	22,222	$50.0K	+3.49%	−63.6%

Chart uses split-adjusted closes from the first print through the latest available bar. Returns use the last close on or before the trade date and the first close on or after 90 and 180 calendar days. Sales are signed so a declining price is a positive result for the seller. Not investment advice.